News
February 26, 2025
Inhalon Biopharma Announces Publication of Phase 1 Clinical Trial Data for IN-006, Its Inhaled Antibody Treatment for COVID-19 Read More
​
February 10, 2025
Inhalon Biopharma to Share Progress in Advancing Inhaled Antibody Therapy Platform for Treating Respiratory Infections at BIO CEO & Investor Conference Read More
​
February 3, 2025
Inhalon Biopharma Announces First-of-its-Kind Inhaled Antibody Treatment for RSV to Enter Human Clinical Trials Read More
​
August 26, 2024
Inhalon Biopharma Announces Poster Presentation at Military Health System Research Symposium 2024 Read More
​
June 3, 2024
Inhalon Biopharma to Provide Update on Inhaled Monoclonal Antibody Therapy Platform at BIO International Convention Read More
​
April 25, 2024
Inhalon Biopharma to Share Progress on Inhaled Monoclonal Antibody Therapy at 9th Annual Inhalation and Respiratory Drug Delivery Congress Read More
​
March 20, 2024
Inhalon Biopharma Announces Positive Results from Study Demonstrating Superior Safety and Efficacy of its Inhaled Antibody Platform Over Systemic Dosing Read More
​
March 14, 2024
Inhalon Biopharma Announces Two Publications Advancing its Inhaled Antibody Treatment Platform for Acute Respiratory Infections Read More
​
January 8, 2024
Inhalon Biopharma to Present on Product Development Pipeline at Biotech Showcase Read More
​
November 15, 2023
Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19 Read More
​
November 1, 2023
Inhalon Biopharma Expands Therapeutic Horizons with Licensing of hMPV Antibodies from the University of Georgia Read More
​
October 6, 2023
Inhalon Biopharma to Share Progress in Development of Inhaled Antibody Platform at the Bio Investor Forum and Bio Europe Read More
​
June 30, 2022
Inhalon Biopharma Closes Series A Financing to Further their Study of Inhaled Antibodies Read More
​
October 7, 2021
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19 Read More
​
July 22, 2021
Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home Read More
​
July 16, 2021
Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer Read More
​
May 26, 2021
Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-trapping” Antibody for the Treatment of COVID-19 Read More